PRODUCT
HIGHLIGHT
A liquid formulation of ATP for intravenous administration
as a new diagnostic test for the identification of an
abnormally slow heart rate (bradycardia) as the cause
of syncope or fainting. 
HEADLINES
Fri,
Jan 27, 2006
DUSKA THERAPEUTICS, INC. Files SEC form 8-K, Change
in Directors or Principal Officers, Financial Statements
and Exhi...
Thu,
Jan 26, 2006
Duska Therapeutics Announces Board Change...
|
